SPRB — Spruce Biosciences Cashflow Statement
0.000.00%
- $3.12m
- -$33.89m
- $4.91m
- 20
- 72
- 12
- 26
Annual cashflow statement for Spruce Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -29.5 | -42.3 | -46.2 | -47.9 | -53 |
Depreciation | |||||
Non-Cash Items | 0.821 | 4.39 | 3.29 | 4.22 | 5.6 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.16 | 1.96 | 1.13 | 10.4 | -8.57 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -27.5 | -35.9 | -41.7 | -33.3 | -56 |
Capital Expenditures | -0.074 | -0.093 | -0.008 | -0.007 | 0 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | -79.1 | 23.7 | 55.8 | 0 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.074 | -79.2 | 23.7 | 55.8 | 0 |
Financing Cash Flow Items | -2.9 | -0.039 | -0.319 | -3.03 | -0.246 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 181 | 0.643 | -0.241 | 49.1 | -1.62 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 153 | -114 | -18.2 | 71.6 | -57.6 |